- Report
- July 2024
- 156 Pages
Global
From €3234EUR$3,613USD£2,825GBP
€3804EUR$4,250USD£3,323GBP
- Report
- February 2026
- 150 Pages
Germany
From €4341EUR$4,850USD£3,792GBP
- Report
- February 2023
- 264 Pages
Global
From €4341EUR$4,850USD£3,792GBP
- Report
- October 2024
- 85 Pages
Global
From €3500EUR$4,189USD£3,164GBP
- Report
- June 2023
- 107 Pages
Global
From €3500EUR$4,189USD£3,164GBP
- Report
- January 2025
- 132 Pages
Global
From €850EUR$950USD£743GBP
- Book
- August 2020
Asia Pacific
The Cancer Liquid Biopsy market is a subset of the Diagnostics industry that focuses on the use of liquid biopsies to detect and monitor cancer. Liquid biopsies are non-invasive tests that use a sample of blood, urine, or other bodily fluid to detect cancer cells or genetic material associated with cancer. This type of biopsy can provide information about the type and stage of cancer, as well as the presence of mutations that may affect treatment options. Liquid biopsies are increasingly being used to monitor cancer progression and response to treatment, as well as to detect cancer recurrence.
Some companies in the Cancer Liquid Biopsy market include Guardant Health, Exosome Diagnostics, Freenome, and Biocept. Show Less Read more